Amazon teams up with Fred Hutchinson to launch cancer vaccine clinical trial
Fred Hutchinson is sponsoring the Phase 1 trial, while Amazon are contributing scientific and machine learning expertise
E-commerce giant Amazon confirmed this week that it is collaborating with the US-based Fred Hutchinson Cancer Research Center to develop cancer vaccines, and recently launched an FDA-approved clinical trial.
Amazon and Fred Hutchinson are currently in the process of recruiting 20 participants over the age of 18 for the Phase 1 trial, which will test the safety and efficacy of vaccines for the treatment of breast cancer and melanoma, according to a recent filing. The vaccine candidate is described as a ‘personalized neo-antigen peptide vaccine’ that combines multiple patient specific neo-antigens.
The study began on June 9, 2022 and is expected to be complete by November 1, 2023. Fred Hutchinson is listed as the study’s sponsor, while Amazon is listed as a collaborator in the filing.
Amazon and Fred Hutchinson have both confirmed the partnership.
Speaking to CPHI, an Amazon spokesperson said the company would be contributing ‘scientific and machine learning expertise’ to the partnership.
They continued: ‘It’s very early, but Fred Hutch recently received permission from the U.S. Food and Drug Administration to proceed with a Phase I clinical trial, and it’s unclear whether it will be successful. This will be a long, multi-year process—should it progress, we would be open to working with other organizations in health care and life sciences that might also be interested in similar efforts.’
Fred Hutchinson added that ‘success is by no means guaranteed’ in a statement to CPHI.
The collaboration is the latest attempt by Amazon to expand its healthcare offering and utilise the work done by its internal R&D teams. In 2020 the company launched an online pharmacy, called Amazon Pharmacy, and in 2021 expanded its telehealth service, Amazon Care. It has also explored the development of at-home medical diagnostics.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance